Skip to main content

An Ounce of Prevention (2.4.2022)

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.  He discusses the GI side effects of IL-17 inhibitors, downstream revenues from rheumatology care and dietary prevention of gout. 

  1. Retrospective study of 84 pts with Erosive Hand OsteoArthritis (EHOA)- 89% females DIPs erosions scores were higher than PIP’s. Comorbid dz = crystal arthritis (8%), RA (5%) & PsA (1%), Pain usually >5/10 w/ 1/3 responding to NSAIDs. Big Unmet need! https://bit.ly/3J3dOUg
  2. Treatment of Complex regional pain syndrome type-I (CRPS-I) in adults is difficult! A Systematic review shows that only parenteral bisphosphonates (and maybe ketamine) lowered VAS/NRS pain scales vs placebo. https://bit.ly/3on52ZB
  3. Poncet’s disease: a reactive arthritis secondary to pulmonary M. tuberculosis https://bit.ly/3gnVNny
  4. Persons living with diagnosed HIV (PLWDH) have more hospitalizations and death from COVID-19 than those not HIV+. In 100K PLWDH, 63%) were fully vaccinated, 4% partly Vax & 32% no Vax. VAX in PLWDH was lower than gen population (63% vs 75%)  https://t.co/oegf5WjmNF
  5. In the USA, the prevalence of Vitiligo in adults is between 0.76% (1.9 million cases in 2020) and 1.11% (2.8 million cases in 2020). Approximately 40% of adult vitiligo in the US may be undiagnosed.  https://t.co/rsyoIbHmS8
  6. Radiographic progression in AxSpA studied in 101 Spanish Pts - pts w/ sustained low ASDAS had less XRay progression than those with active Dz (2.33 vs 1.76, p=0.027). Long term TNFi use didnt influence progression until the 3rd Yr  https://t.co/KHCdzbqhzr
  7. FDA has expanded its approval of REMDESIVIR for use in non-hospitalized adults and pediatric patients for the treatment of mild-to-moderate COVID-19 disease. Previously, Veklury was limited to hospitalized COVID-19 pts. https://t.co/dHbomchfB5
  8. Finnish Parkinson’s disease (FINPARK) cohort (22,189) looked at the assoc w/ #RA. RA pts using only chloroquine/hydroxychloroquine was associated with a lower risk of developing PD (adjusted OR 0.74); not with other DMARDs  https://t.co/yZhgVT0xLh
  9. Systematic review of GI Safety of IL-17 inhibitors included 106 RCTs and 40,053 patients. Inflammatory bowel disease occurred in 0.4%; Most freq Sxs - diarrhea (2.5%), nausea or vomiting (0.7%), and gastroenteritis (0.2%). https://t.co/tv3QXHU1Hg
  10. Study of Academic Clinicians showed that for every $1 generated though office visits (E&M coding) by 5 practicing academic rheums, $12.14 were generated through downstream revenue (mostly infusions).  https://t.co/YQ1RL5JF9u
  11. Article in JAMA estimates that there are 110,000 LESS deaths per year when US adults aged 40-85 years or older had a modest increase in their modest increases in moderate-to-vigorous physical activity intensity per day (ie, 10 minutes per day) https://t.co/n1ictmjnqi
  12. 2021 approved Efgartigimod (Vyvgart) for myasthenia gravis: (binds neonatal Fc receptor, stops Ig recirculation): pts w/ AChR Abs respond best (68% vs 30%). Common AEs include URI, UTI, HA; other AE: eyelid swelling, rash, and SOB. https://t.co/wQKZuAlXoR
  13. Pediatric Rheumatology Workforce Shortages
  14. Healthy Diets Prevent Gout in Women
  15. ACR/EULAR 2022 Classification Criteria for Granulomatosis with Polyangiitis
  16. RheumNow.Live 2022 - Invigorate, Instigate and Debate Rheumatology at RNL 2022
  17. ASK CUSH ANYTHING  Dr. Jan Granieri - AS patient with paradoxical granulomas from a TNF inhibitor?

Join The Discussion

Dr Arthur Weinstein

| Feb 05, 2022 12:23 am

Hi Jack,

Regarding treatment for generalized MG, rheumatologists should be aware that the complement inhibitor eculizumab is now FDA approved.

Best

Art

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject